Safety and Effectiveness of IHAT in Iron Deficient Pre-menopausal Woman

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-06

Study Completion Date

2025-02-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed IHAT (iron hydroxide adipate tartrate) at 2 different doses compared to placebo for increasing serum ferritin levels in iron-deficient but otherwise healthy premenopausal women over 12 weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Effectiveness of Iron Hydroxide Adipate Tartrate (IHAT) in Iron Deficient Premenopausal Women

NCT06285799

Iron-deficiency

COMPLETED PHASE3

A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer

NCT02905539

Anemia, Iron-Deficiency

COMPLETED PHASE4

Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy.

NCT03188445

Iron Deficiency Anemia of Pregnancy

COMPLETED PHASE4

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

NCT03238911

Iron Deficiency Anaemia Iron Deficiency Anemia

COMPLETED PHASE3

A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects

NCT04778072

Premenopause Iron-deficiency Iron Adverse Reaction +2 more

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Iron-deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low dose IHAT

IHAT in capsule form and carob flour in capsule form - taken as 1 x 100mg IHAT capsule (equiv 30mg iron) in the morning with water and 1 x placebo capsule in the evening with water

Group Type EXPERIMENTAL

Low dose IHAT

Intervention Type DRUG

Once daily dose of 1 capsule (100mg per capsule IHAT) and Once daily dose of 1 capsule (carob flour)

High dose IHAT

IHAT in capsule form - taken as 2 x 100mg (equiv 60mg iron) daily with water (1 in the morning and 1 in the evening)

Group Type EXPERIMENTAL

High Dose IHAT

Intervention Type DRUG

Twice daily dose of 1 capsule (100mg per capsule IHAT)

Carob flour

Carob flour in capsule form - taken as 2 x capsules daily with water (1 in the morning and 1 in the evening)

Group Type PLACEBO_COMPARATOR

Carob flour

Intervention Type DRUG

Twice daily dose of 1 capsule (carob flour)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low dose IHAT

Once daily dose of 1 capsule (100mg per capsule IHAT) and Once daily dose of 1 capsule (carob flour)

Intervention Type DRUG

High Dose IHAT

Twice daily dose of 1 capsule (100mg per capsule IHAT)

Intervention Type DRUG

Carob flour

Twice daily dose of 1 capsule (carob flour)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Generally healthy iron deficient pre-menopausal women
* Iron deficiency defined as Serum ferritin \< 30 ug/L (1)
* Generally healthy defined as C-reactive protein \< 3 mg/L (1)
* Subjects adhering to a vegetarian or vegan diet are allowed
* Agree not to give blood donations during the study
* Able to provide informed consent
* Agree not to participate in another clinical trial while enrolled in this trial
* Agree not to change current diet and/or exercise frequency or intensity

Exclusion Criteria

* Anaemia (as determined from the haematocrit and haemoglobin measures) (2)
* Previously told they have an iron absorption problem
* Subjects regularly taking iron specific supplements during or 2 months prior to study commencement (the use of other mineral/vitamin/herbal preparations is allowed but should be recorded) (3)
* Any uncontrolled serious illness (4)
* Receiving/prescribed coumadin (Warfarin), heparin, dalteparin, enoxaparin or other anticoagulation therapy
* Active smokers, nicotine use, alcohol(5) or drug (prescription or illegal substances) abuse
* Chronic gastrointestinal disorders
* Pregnant/lactating women or women trying to conceive
* Diagnosed depression or mental disorder that is uncontrolled
* Eating disorders
* BMI \> 35 kg/m2
* Allergic to any of the ingredients in active or placebo formula
* Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion
* Participants who have participated in any other clinical trial during the past 1 month

Footnotes

1. A blood test is required prior to enrolment into the study to receive trial product. Participants will be required to attend a local pathology collection centre and have serum ferritin and CRP within the required limits to be considered enrolled in the study and be provided with trial product.
2. Anyone considered to be anaemic will be excluded and directed to their GP. In women, anaemia is defined as any of the following: Haemoglobin \< 115 g/L, Haematocrit \< 35%.
3. Potential participants that are taking supplements that would result in their exclusion must wait an 8-week washout period prior to commencing the study.
4. An uncontrolled illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments.
5. Chronic past and/or current alcohol use (\>14 alcohol drinks/week).

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No